Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study
Authors' conclusion
In real-world settings, there was no significant difference in remission rates at 12 months between the tofacitinib and TNFi groups.
Study context
- Population
- Korean patients with RA followed up for at least 12 months, single academic referral hospital's registries of bDMARDs and tofacitinib
- Participants
- 665 patients
- Exposure
- Tofacitinib vs TNFi
- Tofacitinibn = 200
- TNFin = 455reference
- Outcome
- Remission based on DAS28-ESR
- Follow-up
- 12 months
Methodological detailssingle academic referral hospital registries, multivariable logistic regression
- Single academic referral hospital registries
- Multivariable logistic regression
Main finding
DAS28-ESR remission (ITT)
OR for achieving remission (multivariable)
1.204
95% CI 0.720–2.013
By group
Tofacitinibvs TNFi
OR for achieving remission (multivariable) 1.204 (95% CI 0.720–2.013)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR for achieving remission (95% CI) | |
|---|---|---|
| DAS28-ESR remission in JAKi- and bDMARD-naïve subpopulation (subgroup) | 1.867 (1.033–3.377) | |
| 0.20.5125OR for achieving remission (log scale) |
Safety
Adverse events
- Tofacitinib had more adverse events than TNFis
Serious adverse events
- Similar rates with tofacitinib and TNFis
Original publication
Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study. Rheumatology (Oxford). Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →